Elaine J. Heron

Board Director

Director

Biomarin Pharmaceutical Inc Vaxart, Inc.Palvella Therapeutics, Inc.

Insider activity · 24 months2 buys0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 1 buy · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 1 buy · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (2 ops.)

€262k

▼ Sales (0 ops.)

—

Latest filing published 17 Jul 2026 for Vaxart, Inc.. Read the official filing

Filing timeline

BuySale

Elaine J. Heron

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Elaine J. Heron: trading record in brief

This profile gathers the share dealings of Elaine J. Heron across 3 companies, led by Biomarin Pharmaceutical Inc, Vaxart, Inc. and Palvella Therapeutics, Inc. In total, 14 filings cover trades dated from 25 May 2021 to 16 July 2026.

No open-market sale appears; the market trades are 2 purchases worth €262k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 9 share grants and 3 option exercises. So far in 2026, the count stands at 1 purchase and no sales.

Most recently, on 17 July 2026, the filings show a share grant in Vaxart, Inc. The clock since the last published purchase (2 March 2026) now reads 230 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.